Program
AERO-002
A development code. Also written as “AERO-002 (60 mcg)”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive, led by AeroRx Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AeroRx Therapeutics | 31 open or running | phase 2since Feb 14, 2025 | Feb 14, 2025 | Jun 2027phase 2 · NCT07896252 |
Also a collaborator on its studies: medicines-evaluation-unit-ltd.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 14, 2025First study: phase 2 study in Pulmonary Disease, Chronic ObstructiveFirst studyNCT06841640 · 24 enrolled · United Kingdom
- Aug 29, 2026Phase 1 study in Pulmonary Disease, Chronic ObstructiveNCT07802730 · 24 enrolled · United Kingdom
- Oct 14, 2026Phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07896252 · 64 planned · United Kingdom
Ahead
- Jun 2027Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07896252
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07896252Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Recruiting | Jun 2027 | 64 |
| NCT07802730Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | Oct 9, 2026 | 24 |
| NCT06841640Pulmonary Disease, Chronic Obstructive · United Kingdom | 2 | Completed | May 20, 2025 | 24 |
How it is read
Names in the registry
- “AERO-002”, 2 entries
- “AERO-002 (60 mcg)”, 1 entry
Codes read as this program: AERO002.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.